EngineChem Presents Clinical Results Poster of Oral Mucositis Treatment at ASCO

[Asia Economy Reporter Chunhee Lee] Engchem Life Sciences announced on the 17th that it will participate in the 2022 American Society of Clinical Oncology (ASCO) held in Chicago, USA, from the 3rd to the 7th of next month, and present a poster on clinical outcomes of oral mucositis.

ASCO, considered one of the world's top three cancer societies, is an international conference attended by clinical researchers and licensing officers from various countries, including scientists and pharmaceutical company representatives. Various clinical data on new drugs related to cancer treatment are presented, allowing attendees to check the latest clinical trends.

In this presentation, Engchem Life Sciences plans to announce the results of a Phase 2 clinical study confirming the safety, tolerability, and efficacy of 'EC-18' for severe oral mucositis (SOM) occurring in head and neck cancer patients undergoing chemoradiotherapy, conducted by Dr. Christina Henson, a radiation oncology specialist at the University of Oklahoma.

Engchem Life Sciences previously disclosed in March the final results of the Phase 2 clinical trial of the oral mucositis treatment, confirming that both the primary and secondary endpoints were met. The primary endpoint, duration of severe oral mucositis, was reduced by 100% from 13.5 days in the placebo group to 0 days (median) in the treatment group. The secondary endpoint, incidence rate of severe oral mucositis, decreased by 37.1% from 65.0% in the placebo group to 40.9% in the treatment group. The company explained that through this, the maximum tolerated dose, safety, and efficacy of EC-18 were confirmed in Phase 2.

Ki-young Son, Chairman of Engchem Life Sciences, said, "We are pleased to present the clinical outcomes of the oral mucositis treatment at ASCO," adding, "Based on these results, we are preparing for technology export (licensing out) and Phase 3 clinical trials, and are also planning additional clinical trials for various diseases that may occur due to radiation exposure."